In late April 2026, Merck reported first‑quarter results that beat expectations, slightly raised full‑year 2026 sales ...
Merck once again suffers the mixed optics from the updated FY2026 adjusted EPS guidance, attributed to the IPR&D charges.
Merck faces falling sales for other key drugs including a blockbuster HPV vaccine and diabetes medication.
Merck's Q1 sales surpassed expectations, driven by strong demand for Keytruda. Despite acquisition-related losses, investors ...
What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...
First approved by the US FDA in 2014 for advanced skin cancer, Keytruda is now used globally for certain lung cancers, cervical cancer, renal cell cancer and aggressive breast cancer, among others.
After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. The ...
The Drug Controller General of India (DCGI) has approved Keytruda for multiple cancer types. As of recent approvals, it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results